KEAP1 and metabolic dysfunction-associated steatotic liver disease: Activation of Nrf2 alleviated NAFLD symptoms and liver damage, suggesting that compounds modulating the Keap1/Nrf2 signaling pathway may offer valuable therapeutic avenues for NAFLD prevention and management [15,19,20].